Oscar Health, Inc. Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted
Oscar Health, Inc. (OSCR) reported Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted of $280.76 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-08.
Financial Statements › Income Statement › Other Income
us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted · last filed 2025-05-08
- Oscar Health, Inc. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2025-03-31 was $280.76M, a 53.29% increase year-over-year.
- Oscar Health, Inc. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2024-12-31 was -$171.01M.
- Oscar Health, Inc. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2024-09-30 was -$54.60M.
- Oscar Health, Inc. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2024-06-30 was $62.05M.
- Oscar Health, Inc. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2024 was $25.43M.
- Oscar Health, Inc. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2023 was -$270.73M.
- Oscar Health, Inc. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2022 was -$606.27M.
| Period end | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 3 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 6 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 9 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 12 month |
|---|---|---|---|---|
| 2025-03-31 | $280.76M 10-Q · filed 2025-05-08 | $109.75M derived: sum of 2 quarters · filed 2025-05-08 | $55.16M derived: sum of 3 quarters · filed 2025-05-08 | $117.20M derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | -$171.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | -$225.60M derived: sum of 2 quarters · filed 2025-02-20 | -$163.56M derived: sum of 3 quarters · filed 2025-02-20 | $25.43M 10-K · filed 2025-02-20 |
| 2024-09-30 | -$54.60M 10-Q · filed 2024-11-07 | $7.45M derived: sum of 2 quarters · filed 2024-11-07 | $196.44M 10-Q · filed 2024-11-07 | $40.57M derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-06-30 | $62.05M 10-Q · filed 2024-08-07 | $245.20M 10-Q · filed 2024-08-07 | $95.17M derived: sum of 3 quarters · filed 2025-05-08 | $29.77M derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-03-31 | $183.15M 10-Q · filed 2025-05-08 | $33.12M derived: sum of 2 quarters · filed 2025-05-08 | -$32.28M derived: sum of 3 quarters · filed 2025-05-08 | -$47.81M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$150.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | -$215.43M derived: sum of 2 quarters · filed 2025-02-20 | -$230.96M derived: sum of 3 quarters · filed 2025-02-20 | -$270.73M 10-K · filed 2025-02-20 |
| 2023-09-30 | -$65.40M 10-Q · filed 2024-11-07 | -$80.93M derived: sum of 2 quarters · filed 2024-11-07 | -$120.70M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$15.53M 10-Q · filed 2024-08-07 | -$55.30M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | -$39.77M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$606.27M 10-K · filed 2025-02-20 |